TIDMAKR
RNS Number : 0064X
Akers Biosciences, Inc.
16 February 2017
Embargoed: 0700hrs 16 February 2017
Akers Biosciences, Inc.
US Patent for Akers Wellness(TM) Tests Cartridge
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company" or "Akers Bio"), a developer of rapid health information
technologies, announces that the United States Patent and Trademark
Office has allowed a patent covering Akers Bio's proprietary
cartridge for the optical scanning device utilized in the Company's
BreathScan Lync(TM) technology. BreathScan Lync(TM) is the new
bluetooth-enabled reading device from Akers Wellness(TM) which
enables users to track the results of Akers Wellness(TM)
breath-based tests via their mobile device.
The patent covers the unique design of the disposable cartridge
which contains the reagent for the detection of wellness markers.
The reagent contained within is analyzed using optical scanning
technology after contact with the user's exhaled breath sample and
produces a quantitative result through the Akers Wellness(TM) app
on the user's smartphone or tablet. Included in the patent are the
unique form factor, optical lens and read elements and the unique
'U' shaped airflow pathway.
Akers Wellness(TM) breath tests, such as BreathScan OxiChek(TM)
and BreathScan KetoChek(TM), are designed to help promote, track
and/or encourage choices related to general health and wellbeing;
or to support weight loss.
Update on Commercialization of Akers Wellness(TM) Tests
OxiChek(TM) is now fully commercialized and selling through the
Company's distributor, Aero-Med, to anti-aging, functional and
integrative health and wellness treatment practitioners in the
US.
OxiChek(TM) is the first disposable breath test to rapidly
determine levels of oxidative stress in the body by measuring the
levels of certain abundant free radicals. Frequent use of
OxiChek(TM) may help health practitioners to monitor and adjust
their clients' regimen of nutritional supplementation in order to
manage oxidative stress - an indicator of the overall health and
wellbeing of a person.
The Company is ramping up marketing initiatives of OxiChek(TM)
to professionals through enhanced e-commerce and social media
platforms as well as through participation in large trade shows
targeting naturopaths, wellness coaches, anti-aging practitioners,
nutritionists and chiropractors.
In addition to targeting professionals, Akers Wellness(TM)
intends to start marketing OxiChek(TM) through direct-to-consumer
channels during 2017. This will include a television marketing
campaign through the popular Balancing Act national television show
on the Lifetime network. Balancing Act is America's premier morning
show that introduces positive solutions to busy, on-the-go modern
women. Akers Wellness(TM) has completed filming of the program,
which will be aired multiple times on Lifetime during Q2 2017 and
syndicated to approximately 200 affiliates. This marketing
initiative is targeting women aged 25-45 and will potentially reach
approximately 98 million households and thousands of online
viewers.
Akers Wellness(TM) is in discussions with potential distributors
for the KetoChek(TM) test which rapidly determines if the subject
is in the optimal fat-burning state for weight loss, known as
ketosis. Achieving a state of ketosis - as indicated by the measure
of breath ketones - is a goal of many individuals following low
carbohydrate diets. KetoChek(TM) is a simple, non-invasive test to
identify, track and quantitatively monitor breath ketones for
individuals interested in maximizing weight loss.
The Company looks forward to providing further updates on the
commercialization progress of Akers Wellness(TM) tests during
2017.
John J. Gormally, Chief Executive Officer of Akers Bio,
commented:
"We believe Akers Bio's technology for rapidly analyzing
biomarkers in breath condensate is ideally suited for tests in the
expansive US health and wellness market. I am pleased that this
latest patent has been allowed as it is essential that we have
robust protection over our valuable intellectual property.
"OxiChek(TM) is the first fully commercialized Akers
Wellness(TM) test in which this cartridge is applied. We are
pleased that initial sales of this test are being recorded and
excited about the scope for ramping up sales through national
television marketing initiatives and major tradeshow participation.
I look forward to reporting further progress on the Akers
Wellness(TM) product line during the course of 2017."
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Vice Chairman
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUVUNRBSAUAAR
(END) Dow Jones Newswires
February 16, 2017 02:00 ET (07:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024